Supplement-Table 1 Outcomes of SOT recipients in subgroup analyses

|  |  |  |  |
| --- | --- | --- | --- |
| Subgroup analyses | Early CDI, n(%) | Late CDI, n(%)  | Controls, n(%) |
| Survived >90 days post-transplant (N) | 89 | 97 | 5,734 |
| Mortality | 7 (7.9%)† | 6 (6.2%)† | 114 (2.0%) |
| TOH | 47 (52.8%)\*† | 64 (66.0%)† | 1,673 (29.2%) |
| Survived the full follow-up period (N) | 82 | 91 | 5,620 |
| TOH | 41 (50.0%)† | 58 (63.7%)† | 1,582 (28.1%) |
| No recurrent CDI associated hospitalizations (N) | 86 | 88 | 5,913 |
| Mortality | 12 (14.0%)\*† | 3 (3.4%) | 293 (5.0%) |
| TOH | 44 (51.2%)† | 57 (64.8%)† | 1,698 (28.7%) |

\*Compared with the late CDI group, p<0.05; † Compared with the control group, p<0.05. SOT: Solid organ transplant; CDI: *Clostridium difficile* infection; TOH: Transplant organ complications related hospitalization.